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Stanozolol promotes osteogenic gene 
expression and apposition of bone 
mineral in vitro
Stanozolol (ST) is a synthetic androgen with high anabolic potential. 
Although it is known that androgens play a positive role in bone metabolism, 
ST action on bone cells has not been sufficiently tested to support its clinical 
use for bone augmentation procedures. Objective: This study aimed to assess 
the effects of ST on osteogenic activity and gene expression in SaOS-2 cells. 
Material and Methods: SaOS-2 deposition of mineralizing matrix in response 
to increasing doses of ST (0-1000 nM) was evaluated through Alizarin Red S 
and Calcein Green staining techniques at 6, 12 and 24 days. Gene expression 
of runt-related transcription factor 2 (RUNX2), vitamin D receptor (VDR), 
osteopontin (SPP1) and osteonectin (ON) was analyzed by RT-PCR. Results: 
ST significantly influenced SaOS-2 osteogenic activity: stainings showed 
the presence of rounded calcified nodules, which increased both in number 
and in size over time and depending on ST dose. RT-PCR highlighted ST 
modulation of genes related to osteogenic differentiation. Conclusions: This 
study provided encouraging results, showing ST promoted the osteogenic 
commitment of SaOS-2 cells. Further studies are required to validate these 
data in primary osteoblasts and to investigate ST molecular pathway of action.
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Introduction
The research for new strategies and materials to 
enhance bone repair and/or bone regeneration is a 
major goal for the management of demanding clinical 
cases in orthopedics and maxillofacial surgery.
Androgens (or androgenic hormones) can be defined 
as any natural or synthetic steroid that stimulates or 
controls the development and maintenance of primary 
and secondary male characteristics in vertebrates by 
binding to the androgen receptor AR.1 Androgens also 
provide anabolic functions, which result in growth 
and differentiation of cells and increase in body size.2 
Particularly, they play a significant role in regulating 
skeletal morphogenesis and maintaining bone 
homeostasis throughout life.3,4 The most abundant 
circulating androgen in men is testosterone, whose 
effect in peripheral tissues not only depends on a 
direct action, but also results from a local enzymatic 
conversion in different metabolites. 5α-reductase and 
aromatase are among the most important enzymes 
responsible for testosterone transformation in bone 
tissues. 5α-reductase activity reflects in the formation 
of the potent androgen dihydrotestosterone, while 
aromatase catalyzes androgen conversion into the 
estrogen estradiol. Depending on its peripheral 
conversion, systemically administered testosterone 
may bind either to the AR (testosterone itself or 
dihydrotestosterone) or to the estrogen receptors 
ERα/ERβ (testosterone converted to estradiol), which 
results in androgenic or estrogenic effects.5-7
The anabolic potential of androgens leads to the 
synthesis of molecules with a low androgenic and high 
anabolic action, with prolonged activity compared with 
endogenous androgens: these synthetic testosterone-
derivative drugs are generally known as anabolic-
androgenic steroids (AAS). One of these agents is 
stanozolol (ST), a non-aromatizable AAS derived from 
dihydrotestosterone.
Systemic administration of AAS in animal models 
provided some encouraging results, showing an overall 
increase in bone formation and mineralization, as well 
as improvements in bone density and biomechanical 
properties.8-10 Nevertheless, other investigations 
reported qualitative alterations in the bone geometry 
and low bone turnover in response to ST treatment.11 
In brief, the overall efficacy and the long-term safety 
of AAS administration for the osteoporosis therapy 
and the prevention of fracture risk appears to be at 
least questionable.12 Systemic administration, local 
applications of ST and other AAS have been tested 
in animal models to improve bone healing. Such 
approaches allow the use of relatively low doses of 
steroid and imply short-term treatment protocols. 
Intra-articular ST administration showed positive 
effects on the synovial membrane and cartilage 
regeneration in osteoarthritis conditions13, and ST-
soaked deproteinized bone grafts enhanced new bone 
formation in calvarial critical-size defects.14
Although some evidence has been provided in 
human and animal studies, only a limited number 
of studies investigating ST effects on bone cells 
are currently available. SaOS-2 (literally “Sarcoma 
OSteogenic”) cell line represents a validated option 
for the study of osteoblastic differentiation and 
responsiveness to exogenous stimuli. In 1987, 
Rodan, et al. first conducted a study on SaOS-2 
characterization and assessed that these cell lines 
possess several osteoblastic features and could be 
useful as a permanent line of human osteoblast-like 
cells and as a source of bone-related molecules.15
SaOS-2 cells have the advantage of following the 
main molecular steps of osteoblast differentiation and 
have the ability “to deposit a mineralization-competent 
extracellular matrix”.16 Thus, they have been recently 
validated as a feasible model to investigate osteoblast 
activity and maturation.17 Immunocytochemical assays 
revealed that SaOS-2 cells express osteoblast-like 
markers such as osteocalcin (OC or BGLAP) and 
osteopontin (OPN or SPP1). Expression of genes 
involved in osteoblast differentiation and function 
(i.e. runt-related transcription factor 2, RUNX2) 
has been documented.18 Also, the literature data 
provided evidence of SaOS-2 responsiveness to steroid 
stimulation.19
The aim of this study was to assess the effects 
of ST on osteogenic activity and gene expression in 
SaOS-2 cells. The investigation of ST effects on bone 
cells may in fact provide evidence to support the 
clinical use of this steroid in the field of bone healing 
and regeneration, particularly for developing targeted 
drug administration protocols applied to orthopedic, 
maxillofacial and oral surgery.
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Materials and methods
Stanozolol preparation
ST powder (ACME Srl, Reggio Emilia, Italy) was 
weighted and dissolved in absolute ethanol (ETOH), 
preparing 1000X stock solutions. Sequential dilutions 
of stocks were performed in the osteogenic medium, 
to obtain final concentrations of 1 nM, 10 nM, 100 nM, 
500 nM and 1000 nM, respectively.
Cell culture
We preliminarily assessed ST effects on cell 
proliferation using resazurin assay up to 12 days of 
culture.
SaOS-2 cells ranging from 8 to 12 passages were 
plated at a density of 1×104 cells/cm2 into 6-well and 
24-well plates, using respectively 2 mL and 500 μL 
of DMEM-low glucose with 10% fetal bovine serum 
(FBS), penicillin (100 μg/mL), streptomycin (100 μg/
mL) and L-glutamine (2 mM). After 24 h, this medium 
was replaced with an osteogenic medium consisting 
of DMEM-low glucose completed with 2-Phospho-L-
ascorbic acid (100 μM), L-proline (34.8 μM) and β2-
glycerol phosphate (5 mM). The day after (day 0), the 
medium was changed with fresh osteogenic medium 
containing stanozolol at the described concentrations, 
while osteogenic medium with 0.1% ETOH was used 
as a control. The culture medium was changed every 
two/three days.
Culture staining
After 6, 12 or 24 days, cells lying in 24-well plates 
were treated either with Alizarin Red S or Calcein 
Green staining.
Alizarin Red S staining: the cells were washed three 
times with PBS and fixed by adding 250 μL of 4% 
formaldehyde solution for 15 min at room temperature 
and rinsed twice with ddH2O. Then, 500 μL of Alizarin 
Red S solution in water (40 mM, pH 4,2) were added 
to each well, and the whole plates were kept at RT for 
30 min with gentle shaking. The dye was removed, and 
cells were rinsed 5 times (5 min each time) with ddH2O.
To measure Alizarin Red S concentration, each 
well was treated with 200 μL of 10% acetic acid and 
incubated for 30 min at RT with shaking. Cells were 
scraped from the plate and transferred to a 1.5 mL 
microcentrifuge tube and sealed with parafilm. After 
vortexing vigorously for 30 seconds, the samples were 
heated to 85°C for 10 min. Then they were transferred 
on ice for 5 min and centrifuged at 20000 rpm for 15 
min. After centrifugation, the slurry was transferred to 
a new tube, and pH was adjusted to 4.1-4.5 by adding 
75 μL of 10% ammonium hydroxide. An Alizarin Red 
S standard curve was prepared with serial dilutions of 
Alizarin Red ranging from 10 mM to 10 μM, absorbance 
was measured at 405 nm with an Enspire microplate 
reader (Perkin Elmer, Waltham, Massachusetts, USA).
Calcein Green staining: 24 h before the end of 
the experimental period, 2 μl of Calcein Green (10 
mg/mL) were added to each well. At the end of the 
experimental period, the samples were treated with 
500 μl of acetic acid 10% dabbed with ammonium 
hydroxide pH 7.0. The whole plate was placed under 
slow oscillation for 20 min and then placed in an 
ultrasonic bath for 15 min. Each well was then washed 
three times with PBS. Semi-quantitative analysis of 
Calcein Green fluorescence was measured with an 
Enspire microplate fluorescence reader (Perkin Elmer, 
Waltham, Massachusetts, USA) set to a wavelength of 
512 nm, as described elsewhere.20
Gene expression analysis
RNA extraction and reverse transcription: At 12 and 
24 days of culture, total RNA was isolated from cells 
seeded onto 6 well dishes with GenEluteTM Mammalian 
Total RNA Miniprep Kit (Sigma-Aldrich) following the 
manufacturer’s instructions, and 1 μg RNA/sample 
was reverse transcribed to cDNA (GoScript Reverse 
Transcription System, Promega Corporation, Madison, 
Wisconsin, USA). Briefly, RNA on 0.5 μg of random 
hexamer oligonucleotide primers, in a total volume of 
5 μl, was heated to 70°C for 5 min, cooled to 4°C for 
5 min, and then incubated with 15 μl of a mixture of 
components to achieve the final concentration of 0.5 
mM each dNTPs, 1× first-strand buffer, 3 mM MgCl2, 
1 U/μl Recombinant RNasinR Ribonuclease Inhibitor, 
Improm-II 1 μl/reaction, for 1 h at 42°C. The reaction 
was stopped by heating to 70°C for 15 min. The RT 
reaction was then diluted with nuclease free water 
to a total volume of 200 μl, and a triplicate of 5 μl 
aliquots was used for gene expression quantification 
in a 20 μl PCR.
Polymerase chain reaction: The primer set was 
designed according to the known sequences reported 
in GenBank with Primer 3 program [Steve Rozen, 
Helen J. Skaletsky (1998) Primer3. Code available at 
http://www-genome.wi.mit.edu/genome_software/
other/primer3.html.] (Figure 1). cDNA was amplified 
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with 1X GoTaq qPCR Master, 5 pmol specific primers 
and RNase-free water. PCR was performed in a 36-
well Rotor Gene 3000 (Rotor-Gene™ 3000, version 
5.0.60, Mortlake, Australia). Each cycle consisted 
of a denaturation step at 95°C for 15 s, followed by 
separate annealing (15 s, 57°C or 60°C, depending 
on the examined gene) and extension (15 s, 72°C) 
steps. Fluorescence was monitored at the end of 
each extension step. A no-template, no-reverse 
transcriptase control was included in each experiment. 
At the end of the amplification cycles a melting curve 
analysis was added. The data analysis was performed 
according to the Relative Standard Curve Method.21 
Data normalization was carried out in relation to 
the housekeeping gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), which was found to be 
expressed uniformly in all the tested conditions.
Statistical analysis
Growth curves were analyzed using the Boltzmann 
sigmoidal function, and a comparison of curve fits was 
performed to verify the null hypothesis of one curve 
fitting all data sets and the alternative hypothesis 
of different curves for each culture condition. Cell 
differentiation and osteogenic activity was analyzed 
with one-way ANOVA and Tukey’s post-test. A linear 
regression analysis was performed to assess variations 
on different time-points. p<0.05 was considered the 
level of statistical significance. Graphs were obtained 
with GraphPad Prism 6.0 software. Data are expressed 
as mean value ± standard deviation.
Results
Culture staining
Optical microscopy showed a typical polygonal 
shape of SaOS-2, which tended to become slightly 
elongated once they reached confluence. The resazurin 
assay revealed a growth pattern perfectly fitting a 
Sigmoidal Boltzmann curve up to 10 days of culture 
Gene Abbreviation Primer sequences (Forward and Reverse)
Runt-related transcription factor 2 RUNX2
5’-CCA GGC AGG CAC AGT CTT C-3’
5’-GTC AGA GGT GGC AGT GTC ATC-3’
Vitamin D Receptor VDR
5’-CGC ATC ACC AAG GAC AAC C-3’
5’-CTG GCA GAA GTC GGA GTA GG-3’
Alkaline Phosphatase ALP
5’-TGA TGT GGA GTA TGA GAG TGAC-3’
5’-TGA AGT GGG AGT GCT TGT ATC-3’
Osteonectin ON
5’-GCA TCA AGC AGA AGG ATA-3’
5’-AAT AGT TAA GTT ACA GCT AAG AAT-3’
Osteopontin (Secreted Phosphoprotein 1) SPP1
5’-CTC CAT TGA CTC GAA CGA CTC-3’
5’-CGT CTG TAG CAT CAG GGT ACT G-3’
Glyceraldehyde 3-phosphate dehydrogenase GAPDH
5’- TGT TCC TAC CCC CAA TGT GT-3’
5’-GGT CCT CAG TGT AGC CCA AG-3’
Figure 1- Sequences of primers used for RT-PCR
Figure 2- (a) Aspect of SaOS-2 cells at confluency. Optical microscopy, 10X magnification; (b) Graphic representation of SaOS-2 growth 
under different conditions: DMEM-low (red line), ETOH 0.1% (blue line), ST 1-1000 nM (shades of grey). The X axis represents the days 
of culture, whereas the Y axis reports fluorescence values expressed in arbitrary units (A.U.)
a b
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(DMEM low: r2=0.94, ETOH 0.1%: r2=0.96, ST 1nM: 
r2=0.98, ST 10nM: r2=0.93, ST 100nM: r2=0.99, 
ST1000 nM: r2=0.98), while at 12 days of culture 
an overall decrease in cell vitality was recorded 
independently of the culture conditions. A comparison 
of curve fits did not allow us to reject the null 
hypothesis of one curve fitting all data sets (p=0.8), 
thus indicating a superimposable growth pattern of 
SaOS-2 under all the tested conditions up to the end 
of the experimental period. A graphic representation 
of data is reported in Figure 2.
Alizarin Red S staining confirmed the capacity of 
Figure 3- (a) Appearance of SaOS-cell culture treated with different stanozolol (ST) concentrations (0-1000 nM) at 6, 12 and 24 days after 
Alizarin Red S staining. Optical microscopy, 10X magnification; (b) Alizarin Red S staining quantification with different ST concentrations 
(0-1000 nM) at 6, 12 days and 24 days. Data are reported as fold change over controls and expressed as mean ± standard deviation. 
Asterisks indicate statistical significance (*: p<0.05 vs ST 0 nM; ** p<0.005 vs ST 0 nM; ***: p<001 vs ST 0 nM)
a
b
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SaOS-2 to produce calcified extracellular matrix. The 
apposed matrix was characterized by round-shaped 
granules which increased progressively both in size 
and in number depending on the concentration of the 
administered steroid and extent of the induction (Figure 
3a). Cells treated with ST revealed the presence of 
areas with mineralization since the earlier observation 
time-point, which peaked at 1000 nM concentration 
(fold change vs control: ST 1 nM: 1.44±0.08, p>0.05, 
ST 10 nM: 1.47±0.15, p>0.05, ST 100 nM: 1.55±0.15, 
p>0.05, ST 500 nM: 1.64±0.16, p>0.05, ST 1000 nM: 
2.24±0.56, p<0.05). At 12 days, SAOS cell layers 
cultured with ST appeared consistently more filled 
with calcified granules compared with the controls 
at all the tested doses (fold change vs control ST 1 
nM: 1.92±0.08; ST 10 nM: 1.95±0.09; ST 100 nM: 
2.06±0.11; ST 500 nM: 2.10±0.16; ST 1000 nM: 
2.17±0.01, p<0.01). A similar outcome was recorded 
at 24 days (fold change vs control ST 1 nM: 2.02±0.19; 
ST 100 nM: 2.13±0.24; ST 500 nM: 2.25±0.01, ST 
1000 nM: 2.20±0.57, p<0.05) (Figure 3b).
Semiquantitative analysis of Calcein Green 
fluorescence revealed a deposition of calcium 
phosphates in response to ST administration (Figure 
4a). At 6 days’ observation, a dose-dependent 
trend was also evident (fold change vs control ST 
1nM: 1.50±0.16, p>0.05; ST 10 nM: 1.84±0.18, 
p>0.05; ST 100 nM: 3.58±0.54, p<0.005; ST 500 
nM: 4.89±0.46, p<0.01; ST 1000 nM: 11.27±1.06, 
p<0.01). Observations at further time-points revealed 
a massive calcification in all the samples. All the tested 
ST doses produced significantly higher Calcein Green 
fluorescence compared with the controls both at 12 
days (fold change vs control ST 1 nM: 2.03±0.14, 
p<0.05; ST 10 nM: 2.46±0.21, p<0.05; ST 100 
nM: 3.11±0.21, p<0.005; ST 500 nM: 3.21±0.21, 
p<0.005; ST 1000 nM: 4.04±1.06, p<0.05) and 24 
days (fold change vs control ST 1 nM: 1.75±0.10; ST 
10 nM: 1.80±0.04; ST 100 nM: 2.07±0.04; ST 500 
nM: 1.67±0.04; ST 1000 nM: 1.74±0.04; p<0.01) 
(Figure 4b).
Gene expression analysis
The gene expression analysis related to osteogenic 
differentiation revealed differences depending both 
on the time-point (either 12 or 24 days) and on the 
concentration of the steroid (Figure 5).
RUNX2: At 12 days’ observation, the Runx2 
expression was shown to increase at growing 
concentrations of ST, with significant differences vs 
controls for doses ranging from 10 to 1000 nM (fold 
change vs control ST 10 nM: 1.701±0.182, p<0.05; 
ST 100 nM: 1.847±0.226, p<0.005; ST 500 nM: 
2.061±0.143, p<0.001; ST 1000 nM: 2.535±0.295, 
a
b
Figure 4- (a) Appearance of samples treated with stanozolol (ST) (0-1000 nM) at 24 days observation period using a phase contrast 
microscopy and fluorescence microscopy to reveal Calcein Green staining (10X magnification); (b) Graph illustrating fluorescence 
absorbance of Calcein Green staining with different ST concentrations (0-1000 nM) at 6, 12 and 24 days observation period. Data are 
expressed as mean ± standard deviation. Asterisks indicate statistical significance (*: p<0.05 vs ST 0 nM; ** p<0.005 vs ST 0 nM; ***: 
p<001 vs ST 0 nM)
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p<0.001). A similar pattern was recorded at 24 days 
(fold change vs control ST 1 nM: 2.025±0.191; ST 100 
nM: 2.130±0.240; ST 500 nM: 2.250±0.014, ST 1000 
nM: 2.200±0.566, p<0.05). At 24 days, the Runx2 
expression showed a significant increase vs control 





Figure 5- Gene expression of SaOS-2 treated with different concentrations (0-1000 nM) of stanozolol (ST) at 12 and 24 days observation 
period; (a) RUNX2: runt-related transcription factor 2; (b) VDR: Vitamin D Receptor; (c) SPP1: Osteopontin; (d) ON: Osteonectin. Data 
are reported as fold change over 0 nM ST and are expressed as mean ± standard deviation. Asterisks indicate statistical significance (*: 
p<0.05 vs control; ** p<0.005 vs control; ***: p<001 vs control)
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used (fold change vs control ST 1nM: 1.514±0.234, 
p<0.05; ST 10 nM: 1.786±0.201, p<0.005). A 
tendency to decrease at the highest ST concentrations 
(500, 1000 nM) was also detected, although without 
any statistical significance (Figure 5a).
VDR: The VDR expression showed a consistent 
increase vs controls with the administration of the 
highest ST concentrations (fold change vs control 
ST 10 nM: 2.037±0.543, p<0.05; ST 100 nM: 
2.388±0.427, p<0.001; ST 1000 nM: 2.255±0.247, 
p<0.001) at 12 days. At 24 days, all the tested ST 
doses were associated with significantly higher VDR 
expression vs controls (fold change vs control ST 1 nM: 
2.158±0.070; ST 10 nM: 2.622±0.179; ST 100 nM: 
2.770±0.090, ST 1000 nM: 2.901±0.073, p<0.001) 
(Figure 5b).
SPP1: The expression pattern of SPP1 showed 
variations depending on the observation period, with 
no significant differences in test groups vs controls at 
12 days (p>0.05) and a consistent induction observed 
at 24 days for all the tested concentrations of ST (fold 
change vs control ST 1 nM: 2.691±0.145; ST 10 nM: 
2.401±0.416; ST 100 nM: 2.540±0.197; ST 500 nM: 
2.680±0.166, ST 1000 nM: 2.331±0.048, p<0.005) 
(Figure 5c).
ON: The ON gene expression increased in response 
to the higher ST dose of 100 nM (fold change vs 
control: 2.645±0.109, p<0.05) and 1000 nM (fold 
change vs control: 4.175±0.577, p<0.001) at 12 days. 
At 24 days, no significant differences in test groups vs 
controls were recorded (p>0.05) (Figure 5d).
Discussion
This research investigated the effects of different 
doses of ST on the proliferation and osteogenic 
response of SaOS-2 cells. Growing evidence suggests 
androgens act directly on bone cells, playing a 
complex regulatory role.22 Androgen effects on 
osteogenic differentiation are still controversial, 
nevertheless it has been suggested they may stimulate 
osteoblastic differentiation and extracellular bone 
matrix apposition.23-25 Previous authors observed 
the effects of androgenic steroids on cell lines and 
reported positive effects of testosterone at doses of 
10-10 M and 10-9 M on the proliferation of SaOS-2 cells 
after 48 h.26 However, to the best of our knowledge, 
only one study reported on ST effects on osteogenic 
activity of bone cells, concluding that “Stanozolol at a 
concentration of 10−10 mol/l to 10−6 mol/l consistently 
stimulated the incorporation of [3H]thymidine into DNA 
of human bone cells and increased proliferation” up to 
15 days of culture.27
According to our assay, ST treatment at the doses 
of 1 to 1000 nM did not affect the growth pattern of 
SaOS-2 cells up to 12 days of culture. This result may 
be due to the specific characteristics of the steroid 
used, although a peculiarity of the cells used in our 
experimental setting cannot be ruled out. Indeed, 
various SaOS-2 subpopulations that responded 
differently to proliferative and differentiative stimuli 
were identified.28 Moreover, the phenotypic stability of 
SaOS-2 may be affected by the number of passages 
they have undergone: it was noticed that a higher 
passage SaOS-2 demonstrated higher proliferation 
rates and lower alkaline phosphatase activities, 
although mineralization was significantly more 
pronounced in cultures of late passage cells.29 Such 
findings are consistent with our results of an overall 
high proliferation rate of SaOS-2 ranging from 8 to 
12 passages as well as a high mineralizing activity.
Alizarin Red S and Calcein Green staining showed ST 
administration notably increased mineralization. These 
findings highlighted the advantages of treating cells 
with androgens compared with the use of a standard 
differentiation medium. At 12 days’ observation all the 
tested doses showed a similar effect with Alizarin Red 
S quantification technique, whereas a different dose-
dependent effect was recorded with Calcein Green 
staining. These differences may point to a greater 
sensitivity of Calcein Green technique compared with 
Alizarin Red S. Nevertheless, neither Alizarin Red S nor 
Calcein Green revealed any differences between the 
effect of treatment at 24 days’ observation, when all 
the samples presented abundant uniform calcification.
RT-PCR analysis revealed a modulatory role 
played by ST on the gene expression related to 
osteogenic differentiation. RUNX2 represents an early 
differentiation marker, as its expression is enhanced 
since the first stages of osteoblast maturation.30 
The detection of RUNX2 mRNA in control samples 
confirmed previous observations that described a 
constitutive expression of this gene in SaOS-2 cells.18 
In addition, we found out that RUNX2 expression 
may be modulated by steroid treatment: according 
to our results at 12 days, the expression of RUNX2 
was increasing with a dose-dependent trend, 
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consistently with the mineralization pattern (Calcein 
Green staining). We may hypothesize that treatment 
with higher doses of ST induced a faster activation 
in terms of osteo-differentiation and mineralization 
when compared with lower doses. Thus, an overall 
decrease in RUNX2 expression at 24 days in samples 
treated with high doses of ST is compatible with a 
lower mitotic activity and a more mature phenotype. 
On the other hand, lower doses may produce a similar 
effect throughout a longer timeframe. It would be 
interesting to investigate the mineralization pattern 
occurring between 12 and 24 days, as at 24 days we 
observed a massive mineralization, which may mask 
previous differences between samples.
Another hypothesis to explain RUNX2 decrease at 
24 days is that of a biphasic effect of higher ST doses, 
which may improve cell differentiation at early time 
points (12 days) and may not keep this effect at late 
time points (24 days). A biphasic effect of androgens 
on cell viability has been described in the literature, 
with an initial increase in cell proliferation followed 
by a decrease after prolonged exposure.31 However, 
according to our preliminary assay, ST treatment did 
not affect the growth pattern of SaOS-2 up to 12 
days. It would be interesting to investigate whether 
a different effect on cell viability is observed between 
12 and 24 days.
An increase in SPP1 expression in response to 
ST was recorded respectively at 12 and 24 days 
of ST treatment, which first demonstrated the 
modulatory activity of this androgen on genes 
related to osteogenic function. Interestingly, the 
expression pattern of RUNX2 and SPP1 was shown 
to be inversely correlated, with a marked increase of 
SPP1 observed together with a decrease in RUNX2 
expression. This finding may indicate an expression 
switch from 12 to 24 days, as it was observed that in 
SaOS-2 cells RUNX2 repressed SPP1 gene expression, 
and the induction of SPP1 expression during normal 
human osteoblast differentiation has been previously 
related to a decrease in RUNX2.32 Consistently, the 
ON expression pattern revealed that, at the highest 
tested concentration, ST promoted the initial phases of 
osteoblastic commitment (12 days), whereas its action 
was no more evident at a longer time-point (24 days), 
when the differentiation was more advanced. Another 
gene expression that was strongly enhanced by ST 
treatment in our study was VDR, which encodes the 
nuclear hormone receptor for vitamin D3 and has been 
recognized as a key gene for SaOS-2 differentiation 
elsewhere.33 It would be relevant to assess changes 
in the expression of other genes typical of both early 
and late differentiation phases and to set a more 
complete differentiation profile of cells in response to 
growing steroid doses. Moreover, an examination of 
protein levels would be appropriate to validate our RT-
qPCR data, since mRNA expression could not directly 
correlate to protein translation and activity.
A major limitation of this study is represented 
by the lack of assessment of ST receptor binding 
and molecular pathway of action. Since ST is a non-
aromatizable androgen, we may suppose its action 
to be exerted through AR. The expression of AR in 
SaOS-2 cells has been previously described in the 
literature.34 However, the interaction of ST with AR 
and its influence on cell transcriptional activity is still 
unclear: previous studies documented an activation 
of AR in response to ST treatment,35 but also a variety 
of other receptors have been reported as ST ligands 
(including progesterone receptor, estrogen receptor 
alpha and low-affinity glucocorticoid-binding sites).36-39 
Such differences could be dependent on the cell type, 
as ST may have tissue-specific binding sites and elicit 
differential biological responses. According to these 
considerations, it would be relevant to characterize 
SaOS-2 receptor profile, to investigate ST binding 
to AR and to perform blockage tests to verify the 
activation of different molecular pathways in response 
to ST administration.
Finally, we recommend considering potential side 
effects of AAS in further in vivo studies: changes in 
cholesterol levels (increased low-density lipoprotein 
and decreased high-density lipoprotein), liver 
damage, nephropathy, cardiovascular pathologies as 
well as conditions pertaining to hormonal imbalance 
have been reported in response to AAS high-dose or 
prolonged administration.40
Conclusions
This study provided encouraging results, as it 
showed ST promoted the osteogenic commitment of 
SaOS-2 cells, by enhancing the mineralization process 
and modulating the expression of genes related to 
osteogenic differentiation.
Nevertheless, further studies are required to 
validate these data in primary osteoblasts as well 
GHIACCI G, LUMETTI S, MANFREDI E, MORI D, MACALUSO GM, SALA R
J Appl Oral Sci. 2019;27:e2018001410/11
as to investigate ST receptor binding and molecular 
pathway of action.
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